Observational studyJournal of the American Heart Association2020
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
Observational study in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Pharmacological treatments and clinical events in newly diagnosed heart failure patients stratified by ejection fraction in Japan.Scientific reports · 2026Article
- Psychosocial factors, guideline-directed medical therapy, and healthcare resource use among patients newly diagnosed with heart failure in the United States.American heart journal plus : cardiology research and practice · 2026Article
- Drug Adherence After Hospitalisation for Heart Failure: What Have We Learned from a French Survey?Journal of clinical medicine · 2026Article
- Patient Care Pathways and Outcomes Following Newly Diagnosed Atrial Fibrillation.Journal of the American Heart Association · 2026Article
- Risk Stratification Tools in Acute Heart Failure and Their Roles in Personalized Follow-Up.Journal of clinical medicine · 2025Review
- Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review.Biomolecules · 2025Review
- Impact of socio-demographic and ethnic determinants in guideline-directed medical therapy implementation during heart failure hospitalization.European heart journal open · 2025Article
- Systematic Literature Review of the Impact of Type 2 Diabetes and Heart Failure Guideline Adherence on Clinical and Economic Outcomes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Review
- Optimizing Revascularization in Ischemic Cardiomyopathy: Comparative Evidence on the Benefits and Indications of CABG and PCI.Life (Basel, Switzerland) · 2025Review
- Assessing the application of American Heart Association (AHA) guidelines in the management of heart failure with reduced ejection fraction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Challenges Related to Out-of-Pocket Costs in Heart Failure Management.Circulation. Heart failure · 2025Review
- Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score.Journal of the American Heart Association · 2025Article
- Characteristics, health care utilization and cost of patients hospitalized with heart failure.Frontiers in health services · 2025Article
- Comorbidities and determinants of health on heart failure guideline-directed medical therapy adherence: All of us.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Determinants of Guideline-Directed Medical Therapy Implementation During Heart Failure Hospitalization.JACC. Advances · 2024Article
- Optimization of Guideline-Directed Medical Therapy During Hospitalization for Heart Failure: Mind the Gap!JACC. Advances · 2024Article
- Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan.Journal of clinical medicine · 2024Article
- Validation of a New Scoring Method to Assess the Efficacy of Rapid Initiation and Titration of Combination Pharmacotherapy for Patients Hospitalized with Acute Decompensated Heart Failure with Reduced and Mildly Reduced Ejection Fraction.Journal of clinical medicine · 2024Article
- Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF-related hospitalization using the Humana Medicare Advantage database (2008-2016). HF medication classes (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none [23% of patients; n=3987], monotherapy [22%; n=3777], dual therapy [41%; n=7056], or triple therapy [13%; n=2286]). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio [95% CI]) with monotherapy (0.68 [0.64-0.71]), dual therapy (0.56 [0.53-0.59]), and triple therapy (0.45 [0.41-0.50]). Nearly half (46%) of patients who received post-discharge medication had no dose escalation. Overall, 59% of patients had follow-up with a primary care physician within 14 days of discharge, and 23% had follow-up with a cardiologist. Conclusions In real-world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline-recommended dual and triple HF therapy remained low. There are opportunities to improve post-discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post-discharge follow-up with providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.